← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Afya Limited (AFYA) 10-Year Financial Performance & Capital Metrics

AFYA • • Industrial / General
Consumer DefensiveEducation & TrainingHigher Education & Professional TrainingMedical & Healthcare Education
AboutAfya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.Show more
  • Revenue $3.3B +14.9%
  • EBITDA $1.22B +15.1%
  • Net Income $632M +63.5%
  • EPS (Diluted) 6.93 +62.3%
  • Gross Margin 63.21% +2.9%
  • EBITDA Margin 36.81% +0.2%
  • Operating Margin 30.63% +14.8%
  • Net Margin 19.11% +42.3%
  • ROE 15.88% +41.7%
  • ROIC 12.3% +13.8%
  • Debt/Equity 0.74 +0.2%
  • Interest Coverage 2.76 +39.1%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y profit CAGR of 32.6%
  • ✓FCF machine: 31.5% free cash flow margin
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 34.5%
  • ✓Healthy 5Y average net margin of 17.2%
  • ✓Trading at only 0.3x book value

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y34.5%
3Y24.33%
TTM14.07%

Profit (Net Income) CAGR

10Y-
5Y32.62%
3Y41.41%
TTM25.84%

EPS CAGR

10Y-
5Y27.96%
3Y43%
TTM25.63%

ROCE

10Y Avg23.66%
5Y Avg11.39%
3Y Avg12.43%
Latest14.24%

Peer Comparison

Medical & Healthcare Education
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
ATGEAdtalem Global Education Inc.4.26B117.3919.3412.85%13.74%17.29%6.74%0.54
AFYAAfya Limited674.82M14.392.0814.9%20.08%15.24%100%0.74

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+216.01M333.94M750.63M1.2B1.72B2.33B2.88B3.3B
Revenue Growth %-0.55%1.25%0.6%0.43%0.35%0.23%0.15%
Cost of Goods Sold+124.06M168.05M308.85M434.65M652.3M859.55M1.11B1.22B
COGS % of Revenue0.57%0.5%0.41%0.36%0.38%0.37%0.39%0.37%
Gross Profit+91.94M165.88M441.78M766.54M1.07B1.47B1.77B2.09B
Gross Margin %0.43%0.5%0.59%0.64%0.62%0.63%0.61%0.63%
Gross Profit Growth %-0.8%1.66%0.74%0.39%0.38%0.2%0.18%
Operating Expenses+42.6M69.44M236.53M403.2M626.18M805.58M999.04M1.08B
OpEx % of Revenue0.2%0.21%0.32%0.34%0.36%0.35%0.35%0.33%
Selling, General & Admin45.35M70.03M239.12M402.86M622.62M798.15M1.01B1.07B
SG&A % of Revenue0.21%0.21%0.32%0.34%0.36%0.34%0.35%0.32%
Research & Development00032K09.44M21.5M20.09M
R&D % of Revenue---0%-0%0.01%0.01%
Other Operating Expenses-2.75M-599K-2.59M347K3.56M0-37.15M-11M
Operating Income+49.34M96.45M205.25M363.33M440.89M664.1M767.06M1.01B
Operating Margin %0.23%0.29%0.27%0.3%0.26%0.29%0.27%0.31%
Operating Income Growth %-0.95%1.13%0.77%0.21%0.51%0.16%0.32%
EBITDA+53.52M106.07M278.4M472.84M595.12M876.04M1.06B1.22B
EBITDA Margin %0.25%0.32%0.37%0.39%0.35%0.38%0.37%0.37%
EBITDA Growth %-0.98%1.62%0.7%0.26%0.47%0.21%0.15%
D&A (Non-Cash Add-back)4.18M9.62M73.15M109.5M154.22M211.94M289.51M204.12M
EBIT49.34M96.45M242.41M363.33M449.11M717.09M815.88M1.01B
Net Interest Income+-381K-573K-51.38M-9.22M-152.61M-261.45M-279.17M-322.94M
Interest Income3.17M4.36M9.04M7.05M23.04M27.2M107.12M43.42M
Interest Expense1.04M2.4M15.94M16.27M175.65M288.65M386.3M366.35M
Other Income/Expense1.64M2.27M-18.31M-28.28M-167.43M-235.67M-337.48M-335.72M
Pretax Income+50.98M98.72M186.94M335.05M273.46M428.43M429.58M676.39M
Pretax Margin %0.24%0.3%0.25%0.28%0.16%0.18%0.15%0.2%
Income Tax+2.5M3.99M14.18M27.07M31.18M35.68M24.17M27.47M
Effective Tax Rate %0.89%0.87%0.82%0.87%0.82%0.87%0.9%0.93%
Net Income+45.39M86.35M153.92M292.07M223.33M373.57M386.32M631.51M
Net Margin %0.21%0.26%0.21%0.24%0.13%0.16%0.13%0.19%
Net Income Growth %-0.9%0.78%0.9%-0.24%0.67%0.03%0.63%
Net Income (Continuing)48.48M94.73M172.76M307.99M242.28M392.76M405.42M648.92M
Discontinued Operations00000000
Minority Interest651K88.37M48.63M51.56M51.87M51.32M41.51M40.63M
EPS (Diluted)+0.520.982.023.122.374.154.276.93
EPS Growth %-0.88%1.06%0.54%-0.24%0.75%0.03%0.62%
EPS (Basic)0.520.982.033.152.394.154.277.01
Diluted Shares Outstanding87.68M87.68M76.19M93.64M94.1M89.94M90.54M91.15M
Basic Shares Outstanding87.68M87.68M75.97M92.68M93.29M89.94M90.47M90.12M
Dividend Payout Ratio--0.25%-----

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+60.48M133.5M1.11B1.41B1.21B1.64B1.2B1.59B
Cash & Short-Term Investments25.49M62.26M943.21M1.05B748.56M1.09B553.03M911.01M
Cash Only25.49M62.26M943.21M1.05B748.56M1.09B553.03M911.01M
Short-Term Investments00000000
Accounts Receivable31.13M58.45M125.44M302.32M403.93M480.64M546.44M621.62M
Days Sales Outstanding52.663.886191.8685.7575.3269.3568.67
Inventory448K1.11M3.93M7.51M11.83M12.19M1.38M0
Days Inventory Outstanding1.322.424.656.316.625.180.45-
Other Current Assets3.41M11.12M164.62M50.63M42.53M51.74M102.66M57.15M
Total Non-Current Assets+43.15M784.92M1.8B3.39B5.24B5.56B6.38B7.24B
Property, Plant & Equipment32.48M65.76M413.6M679.46M1.08B1.23B1.38B1.5B
Fixed Asset Turnover6.65x5.08x1.81x1.77x1.59x1.89x2.09x2.20x
Goodwill0169.53M459.41M810.66M1.18B1.26B1.33B1.53B
Intangible Assets4.73M512.93M852.93M1.76B2.72B2.78B3.46B4.01B
Long-Term Investments3.26M26.31M45.63M51.41M48.48M53.91M51.83M54.44M
Other Non-Current Assets5.94M36.69M19.32M76.09M207.75M234.32M156.83M151.82M
Total Assets+103.63M918.42M2.91B4.79B6.45B7.2B7.58B8.83B
Asset Turnover2.08x0.36x0.26x0.25x0.27x0.32x0.38x0.37x
Asset Growth %-7.86%2.17%0.65%0.35%0.12%0.05%0.16%
Total Current Liabilities+51.94M182.33M333.23M589.38M766.51M905.69M1.06B1.14B
Accounts Payable6.74M8.1M149.51M224.16M298.95M333.19M108.22M128.08M
Days Payables Outstanding19.8317.6176.69188.24167.28141.4935.5938.46
Short-Term Debt1.16M26.8M53.61M117.67M143.2M207.38M179.25M363.55M
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K00
Other Current Liabilities24.14M108.99M47.9M84.19M146.46M157.24M514.14M361.45M
Current Ratio1.16x0.73x3.34x2.38x1.57x1.81x1.14x1.39x
Quick Ratio1.16x0.73x3.32x2.37x1.56x1.79x1.14x1.39x
Cash Conversion Cycle34.0948.7-111.05-90.07-74.91-60.9934.21-
Total Non-Current Liabilities+4.92M145.73M465.5M1.37B2.68B3.04B2.88B3.38B
Long-Term Debt2.66M51.03M6.75M576M1.3B1.74B1.62B1.83B
Capital Lease Obligations00261.82M385.73M689.13M737.07M837.67M932.76M
Deferred Tax Liabilities00000000
Other Non-Current Liabilities2.26M94.7M196.93M408.21M687.35M568.93M423.71M614.4M
Total Liabilities56.86M328.06M798.73M1.96B3.45B3.95B3.94B4.52B
Total Debt+3.82M77.83M344.87M1.14B2.16B2.71B2.68B3.17B
Net Debt-21.67M15.57M-598.34M96.33M1.41B1.62B2.12B2.26B
Debt / Equity0.08x0.13x0.16x0.40x0.72x0.84x0.73x0.74x
Debt / EBITDA0.07x0.73x1.24x2.41x3.63x3.10x2.53x2.61x
Net Debt / EBITDA-0.40x0.15x-2.15x0.20x2.37x1.85x2.01x1.86x
Interest Coverage47.35x40.12x12.88x22.33x2.51x2.30x1.99x2.76x
Total Equity+46.76M590.35M2.11B2.83B3B3.25B3.64B4.31B
Equity Growth %-11.62%2.58%0.34%0.06%0.08%0.12%0.18%
Book Value per Share0.536.7327.7430.2631.8836.1440.2447.29
Total Shareholders' Equity46.11M501.98M2.07B2.78B2.95B3.2B3.6B4.27B
Common Stock66.48M315M17K17K17K17K17K17K
Retained Earnings40.31M52.58M115.92M407.99M631.32M1B1.38B2.01B
Treasury Stock0000-152.63M-304.95M-299.15M-273.95M
Accumulated OCI43.21M59.81M115.92M50.72M000187.5M
Minority Interest651K88.37M48.63M51.56M51.87M51.32M41.51M40.63M

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+39.92M80.32M299.22M371.51M630.87M843.9M1.04B1.43B
Operating CF Margin %0.18%0.24%0.4%0.31%0.37%0.36%0.36%0.43%
Operating CF Growth %-1.01%2.73%0.24%0.7%0.34%0.24%0.37%
Net Income50.98M98.72M186.94M335.05M273.46M428.43M429.58M676.39M
Depreciation & Amortization4.02M9.08M73.15M108.74M154.22M206.22M289.51M333.34M
Stock-Based Compensation02.16M18.11M32.61M43.38M31.27M31.54M32.42M
Deferred Taxes05.29M-9.86M00000
Other Non-Cash Items-427K1.5M55.47M64.24M208.6M287.89M352.39M409.87M
Working Capital Changes-14.66M-36.44M-24.6M-169.14M-48.8M-109.92M-59.39M-19.36M
Change in Receivables-9.79M-28.2M-35.56M-178M-81.99M-129.16M-131.34M-79.34M
Change in Inventory-140K-593K-236K-3.11M-3.72M-363K10.95M0
Change in Payables-2.38M-1.53M3.03M4.47M14.48M9.97M24.5M18.13M
Cash from Investing+-22.07M-262.39M-354.15M-1.04B-1.27B-591.47M-1.14B-1.09B
Capital Expenditures-21.07M-21.69M-121.71M-89.83M-125.87M-297.02M-118.44M-136.92M
CapEx % of Revenue0.1%0.06%0.16%0.07%0.07%0.13%0.04%0.04%
Acquisitions--------
Investments--------
Other Investing-1M-19.4M9.13M-32.97M-143.17M6.75M-117.09M-327.12M
Cash from Financing+-4.13M218.84M921.43M756.42M364.68M92.94M-439.94M23.97M
Debt Issued (Net)--------
Equity Issued (Net)--------
Dividends Paid00-38.75M00000
Share Repurchases--------
Other Financing-2.51M150.46M36.15M-27.24M-103.3M-221.32M-288.76M-297.71M
Net Change in Cash--------
Free Cash Flow+18.85M58.63M177.51M233.92M354.07M546.88M798.2M1.04B
FCF Margin %0.09%0.18%0.24%0.19%0.21%0.23%0.28%0.31%
FCF Growth %-2.11%2.03%0.32%0.51%0.54%0.46%0.3%
FCF per Share0.210.672.332.503.766.088.8211.41
FCF Conversion (FCF/Net Income)0.88x0.93x1.94x1.27x2.82x2.26x2.70x2.27x
Interest Paid00000000
Taxes Paid00000000

Key Ratios

Metric20172018201920202021202220232024
Return on Equity (ROE)97.07%27.11%11.38%11.81%7.66%11.95%11.21%15.88%
Return on Invested Capital (ROIC)147.47%22.93%14.51%12.26%9.01%10.73%10.82%12.3%
Gross Margin42.56%49.68%58.85%63.81%62.06%63.09%61.41%63.21%
Net Margin21.01%25.86%20.5%24.32%12.99%16.04%13.43%19.11%
Debt / Equity0.08x0.13x0.16x0.40x0.72x0.84x0.73x0.74x
Interest Coverage47.35x40.12x12.88x22.33x2.51x2.30x1.99x2.76x
FCF Conversion0.88x0.93x1.94x1.27x2.82x2.26x2.70x2.27x
Revenue Growth-54.59%124.78%60.02%43.14%35.46%23.48%14.9%

Frequently Asked Questions

Valuation & Price

Afya Limited (AFYA) has a price-to-earnings (P/E) ratio of 2.1x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Afya Limited (AFYA) reported $3.63B in revenue for fiscal year 2024. This represents a 1582% increase from $216.0M in 2017.

Afya Limited (AFYA) grew revenue by 14.9% over the past year. This is steady growth.

Yes, Afya Limited (AFYA) is profitable, generating $729.4M in net income for fiscal year 2024 (19.1% net margin).

Dividend & Returns

Afya Limited (AFYA) has a return on equity (ROE) of 15.9%. This is reasonable for most industries.

Afya Limited (AFYA) generated $1.26B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.